Fig. 5: In vitro and in vivo synergistic chemotherapy and NIR-II PTT via PEGylated MSbNSs-3/DOX.
From: Degradable mesoporous semimetal antimony nanospheres for near-infrared II multimodal theranostics
a Confocal microscopy images of panc02 cancer cells to show the internalization of PEGylated MSbNSs-3/DOX. b Cell viability of panc02 cells treated with PEGylated MSbNSs-3, PEGylated MSbNSs-3 + laser, PEGylated MSbNSs/DOX, and PEGylated MSbNSs-3/DOX + laser. Data are expressed as means ± SD (n = 3). c PA images showing changes in PA signal (red) over time with PEGylated MSbNSs-3/DOX being injected at the tumor site. A representative image of two individual mice per group is shown. d IR thermal images of panc02-tumor mice injected with PBS and PEGylated MSbNSs-3 in response to 1210 laser irradiation. A representative image of three individual mice per group is shown. e Schematic illustration of in vivo photothermal triggered degradation and the change of PA images before and after irradiation for 15 min. f Biodistribution of PEGylated MSbNSs-3 using ICP to measure the concentration of Sb element in major organs. Data are expressed as means ± SD (n = 3). g Tumor growth curves. P-values were calculated by Student’s two-sided t-test. (***P < 0.001), h body weight, and i survival proportions of mice after systemic treatment with PBS, PBS + laser, PEGylated MSbNSs-3 + laser, PEGylated MSbNSs-3/DOX, and PEGylated MSbNSs-3/DOX + laser. Data are expressed as means ± SD (n = 8). j H&E and TUNEL staining for tumor acquired 24 h after systemic treatment. A representative image of 3 individual mice per group is shown.
